Assess whether pediatric studies are necessary or waivable (852152)

Situation

In a mid-size sponsor after a complete response letter, complete-response-letter deficiency list is the evidence after a literature paper the 505(b)(2) package leans on getting retracted. Pharmacovigilance medical reviewer has to pick Pediatric studies are necessary or Waivable for this Pharma & Life Sciences CMC and Development Pathways close using complete-response-letter deficiency list.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Pediatric studies are necessary / Waivable using complete-response-letter deficiency list after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• Pharmacovigilance medical reviewer can defend Pediatric studies are necessary from complete-response-letter deficiency list after a literature paper the 505(b)(2) package leans on getting retracted in a Pharma & Life Sciences challenge.
• Pharmacovigilance medical reviewer cannot defend Pediatric studies are necessary from complete-response-letter deficiency list; Waivable is what the extract actually supports after a literature paper the 505(b)(2) package leans on getting retracted.
• A literature paper the 505(b)(2) package leans on getting retracted never reached the population in complete-response-letter deficiency list — reopen intake, do not close pediatric studies are necessary.
• Two facts in complete-response-letter deficiency list after a literature paper the 505(b)(2) package leans on getting retracted conflict for pharmacovigilance medical reviewer; hold this CMC and Development Pathways file.

Analysis required

• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a literature paper the 505(b)(2) package leans on getting retracted.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read complete-response-letter deficiency list against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move pediatric studies are necessary for pharmacovigilance medical reviewer.

Recommendation